<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03173287</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-327</org_study_id>
    <secondary_id>2016-A02066-45</secondary_id>
    <nct_id>NCT03173287</nct_id>
  </id_info>
  <brief_title>Quantification of Hepatic Fibrosis by IVIM Sequences in 1.5T MRI</brief_title>
  <acronym>IVIM-MRI</acronym>
  <official_title>Quantification of Hepatic Fibrosis by IVIM Sequences in 1.5T MRI.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Quantification of hepatic fibrosis by IVIM sequences in 1.5T MRI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Early and accurate diagnosis of hepatic fibrosis in patients with chronic liver disease is
      essential and essential. This assessment could be performed by a non-invasive MRI method.

      The main objective of this study is to show that the measured perfusion-related scattering
      value (D *) is related to the hepatic fibrosis stage.

      Secondary objectives

        -  Evaluation of infusion fraction (f) and fibrosis stage.

        -  Evaluation of molecular diffusion (D) and fibrosis stage.

        -  Evaluation of ADC and fibrosis stage.

        -  Assess whether there is a link between the etiology of fibrosis and the value of the
           diffusion.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Actual">March 1, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Measured perfusion-related scattering value</measure>
    <time_frame>at day 1</time_frame>
    <description>The main objective of this study is to show that the measured perfusion-related scattering value (D *) is related to the hepatic fibrosis stage.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measured perfusion-related of infusion fraction</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measured perfusion-related of molecular diffusion</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measured perfusion-related of ADC</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Liver Fibrosis</condition>
  <condition>MRI</condition>
  <condition>IVIM</condition>
  <condition>Liver Biopsy</condition>
  <arm_group>
    <arm_group_label>Patients with hepatic biopsy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients having benefited from a hepatic biopsy for evaluation of the hepatic fibrosis, will benefit in 10 days of a MRI in the service of radiology of the hospital Gabriel Montpied.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Quantification of liver fibrosis</intervention_name>
    <description>Procedure MRI and liver biopsy</description>
    <arm_group_label>Patients with hepatic biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing hepatic biopsy (trans-parietal or trans-jugular) in the context of
             liver disease

          -  Signature of written consent

        Exclusion Criteria:

          -  Contra-indications to MRI

          -  Refusal of protocol

          -  Underage patients and protected adults
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benoit MAGNIN</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick LACARIN</last_name>
    <phone>04 73 75 11 95</phone>
    <email>placarin@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <state>Auvergne</state>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick LACARIN</last_name>
      <phone>04 73 75 11 95</phone>
      <email>placarin@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Benoit MAGNIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2017</study_first_submitted>
  <study_first_submitted_qc>May 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2017</study_first_posted>
  <last_update_submitted>May 31, 2017</last_update_submitted>
  <last_update_submitted_qc>May 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatic fibrosis</keyword>
  <keyword>IVIM</keyword>
  <keyword>1.5T MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

